445 related articles for article (PubMed ID: 26968398)
1. Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
Rangel MC; Bertolette D; Castro NP; Klauzinska M; Cuttitta F; Salomon DS
Breast Cancer Res Treat; 2016 Apr; 156(2):211-26. PubMed ID: 26968398
[TBL] [Abstract][Full Text] [Related]
2. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
[TBL] [Abstract][Full Text] [Related]
3. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
4. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
5. Mammary gland stem cells and their application in breast cancer.
Yang X; Wang H; Jiao B
Oncotarget; 2017 Feb; 8(6):10675-10691. PubMed ID: 27793013
[TBL] [Abstract][Full Text] [Related]
6. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.
Sulaiman A; Sulaiman B; Khouri L; McGarry S; Nessim C; Arnaout A; Li X; Addison C; Dimitroulakos J; Wang L
FEBS Lett; 2016 Dec; 590(24):4606-4616. PubMed ID: 27859250
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
[TBL] [Abstract][Full Text] [Related]
8. YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer.
Quinn HM; Vogel R; Popp O; Mertins P; Lan L; Messerschmidt C; Landshammer A; Lisek K; Château-Joubert S; Marangoni E; Koren E; Fuchs Y; Birchmeier W
Cancer Res; 2021 Apr; 81(8):2116-2127. PubMed ID: 33574090
[TBL] [Abstract][Full Text] [Related]
9. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.
Czerwińska P; Shah PK; Tomczak K; Klimczak M; Mazurek S; Sozańska B; Biecek P; Korski K; Filas V; Mackiewicz A; Andersen JN; Wiznerowicz M
Oncotarget; 2017 Jan; 8(1):863-882. PubMed ID: 27845900
[TBL] [Abstract][Full Text] [Related]
10. Wnt signaling, stem cells, and the cellular origin of breast cancer.
Lindvall C; Bu W; Williams BO; Li Y
Stem Cell Rev; 2007 Jun; 3(2):157-68. PubMed ID: 17873348
[TBL] [Abstract][Full Text] [Related]
11. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.
Bao B; Prasad AS
Adv Exp Med Biol; 2019; 1152():311-334. PubMed ID: 31456192
[TBL] [Abstract][Full Text] [Related]
12. Mammary development and breast cancer: the role of stem cells.
Ercan C; van Diest PJ; Vooijs M
Curr Mol Med; 2011 Jun; 11(4):270-85. PubMed ID: 21506923
[TBL] [Abstract][Full Text] [Related]
13. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
14. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer stem cells: Features, key drivers and treatment options.
Dittmer J
Semin Cancer Biol; 2018 Dec; 53():59-74. PubMed ID: 30059727
[TBL] [Abstract][Full Text] [Related]
16. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
[TBL] [Abstract][Full Text] [Related]
17. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
[TBL] [Abstract][Full Text] [Related]
18. The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer.
Doherty MR; Jackson MW
DNA Cell Biol; 2018 Jun; 37(6):513-516. PubMed ID: 29750542
[TBL] [Abstract][Full Text] [Related]
19. Key signaling nodes in mammary gland development and cancer: β-catenin.
Incassati A; Chandramouli A; Eelkema R; Cowin P
Breast Cancer Res; 2010; 12(6):213. PubMed ID: 21067528
[TBL] [Abstract][Full Text] [Related]
20. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
